BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 15050905)

  • 1. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
    Bagger YZ; Tankó LB; Alexandersen P; Hansen HB; Møllgaard A; Ravn P; Qvist P; Kanis JA; Christiansen C
    Bone; 2004 Apr; 34(4):728-35. PubMed ID: 15050905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
    Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
    Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial.
    Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Pallonen H; Saarikoski S; Honkanen R; Mäenpää PH
    J Bone Miner Res; 2003 Feb; 18(2):319-24. PubMed ID: 12568409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures.
    Stone KL; Seeley DG; Lui LY; Cauley JA; Ensrud K; Browner WS; Nevitt MC; Cummings SR;
    J Bone Miner Res; 2003 Nov; 18(11):1947-54. PubMed ID: 14606506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women.
    Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Saarikoski S; Honkanen R; Mäenpää PH
    J Bone Miner Res; 2000 Dec; 15(12):2479-86. PubMed ID: 11127213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmenopausal osteoporosis and hormone replacement therapy.
    Gambacciani M; Vacca F
    Minerva Med; 2004 Dec; 95(6):507-20. PubMed ID: 15785435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of hormone replacement therapy on bone mineral content and on fractures].
    Eiken PA
    Ugeskr Laeger; 1997 Jan; 159(5):570-6. PubMed ID: 9045445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and treatment of osteoporosis with hormone replacement therapy.
    Christiansen C
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():45-54. PubMed ID: 8499959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mineral density and bone loss measured at the radius to predict the risk of nonspinal osteoporotic fracture.
    Gnudi S; Malavolta N; Lisi L; Ripamonti C
    J Bone Miner Res; 2001 Jun; 16(6):1130-5. PubMed ID: 11393790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of hormone replacement therapy and resistance training on spine bone mineral density in early postmenopausal women.
    Maddalozzo GF; Widrick JJ; Cardinal BJ; Winters-Stone KM; Hoffman MA; Snow CM
    Bone; 2007 May; 40(5):1244-51. PubMed ID: 17291843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
    Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
    Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
    Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
    Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
    Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.